LT3111938T - Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi - Google Patents

Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi

Info

Publication number
LT3111938T
LT3111938T LTEP16166266.3T LT16166266T LT3111938T LT 3111938 T LT3111938 T LT 3111938T LT 16166266 T LT16166266 T LT 16166266T LT 3111938 T LT3111938 T LT 3111938T
Authority
LT
Lithuania
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
zinc
Prior art date
Application number
LTEP16166266.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Cai Xiong
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Original Assignee
Curis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis, Inc. filed Critical Curis, Inc.
Publication of LT3111938T publication Critical patent/LT3111938T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP16166266.3T 2011-04-01 2012-03-30 Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi LT3111938T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
LT3111938T true LT3111938T (lt) 2019-06-25

Family

ID=46931927

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16166266.3T LT3111938T (lt) 2011-04-01 2012-03-30 Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi

Country Status (29)

Country Link
US (7) US8710219B2 (enExample)
EP (2) EP3111938B1 (enExample)
JP (3) JP6242331B2 (enExample)
KR (2) KR20180108848A (enExample)
CN (2) CN103582483B (enExample)
AU (1) AU2012236367B2 (enExample)
BR (1) BR112013025340B1 (enExample)
CA (1) CA2830822C (enExample)
CL (1) CL2013002823A1 (enExample)
CY (2) CY1117785T1 (enExample)
DK (2) DK3111938T3 (enExample)
EA (1) EA022434B9 (enExample)
ES (2) ES2577982T3 (enExample)
HR (2) HRP20160545T1 (enExample)
HU (2) HUE028910T2 (enExample)
IL (2) IL228588A (enExample)
LT (1) LT3111938T (enExample)
ME (2) ME02451B (enExample)
MX (1) MX340577B (enExample)
PE (1) PE20141382A1 (enExample)
PL (2) PL3111938T3 (enExample)
PT (2) PT2694075T (enExample)
RS (2) RS54903B1 (enExample)
SG (2) SG10201602569RA (enExample)
SI (2) SI2694075T1 (enExample)
SM (2) SMT201900435T1 (enExample)
TW (1) TWI571469B (enExample)
WO (1) WO2012135571A1 (enExample)
ZA (2) ZA201307082B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
CA2830822C (en) * 2011-04-01 2018-10-02 Curis, Inc. A thienopyrimidine phosphoinositide 3-kinase inhibitor with a zinc binding moiety
JP6051434B2 (ja) 2011-11-14 2016-12-27 イグニタ、インク. AXLおよびc−METキナーゼ阻害剤としてのウラシル誘導体
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
KR102015826B1 (ko) * 2015-04-21 2019-08-29 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도
US11142552B2 (en) * 2016-07-19 2021-10-12 National Institute Of Plant Genome Research Protein against fungal pathogens
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2018360845B2 (en) * 2017-11-06 2024-05-02 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
ES3014591T3 (en) 2018-09-11 2025-04-23 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
CN100503599C (zh) 2002-03-13 2009-06-24 詹森药业有限公司 作为组蛋白脱乙酰酶的新颖抑制剂的羰基氨基衍生物
WO2003076400A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
KR20040090978A (ko) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
CA2514407C (en) 2003-01-29 2012-01-03 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US8227636B2 (en) * 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
JP4862654B2 (ja) 2004-10-08 2012-01-25 アステラス製薬株式会社 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20080213399A1 (en) 2005-02-03 2008-09-04 Topotarget Uk Limited Combination Therapies Using Hdac Inhibitors
EP1885710B1 (en) 2005-05-18 2015-08-19 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
ES2396986T3 (es) 2006-01-19 2013-03-01 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
EP1979328B1 (en) 2006-01-19 2012-12-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007127175A2 (en) * 2006-04-26 2007-11-08 F. Hoffmann-La Roche Ag Pharmaceutical compounds
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス,インコーポレイテッド 亜鉛結合部分を含むキナゾリン系egfrインヒビター
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
RU2459811C2 (ru) 2006-10-28 2012-08-27 Метилджен Инк. Ингибиторы гистоновой деацетилазы
AU2007329352B2 (en) 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2114950B1 (en) * 2006-12-07 2016-03-09 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
EP2136809A4 (en) 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 PI3K/mTOR阻害剤
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
EP2405916B1 (en) 2009-03-12 2018-02-07 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
PH12012500709A1 (en) 2009-10-12 2012-10-29 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療
CA2830822C (en) * 2011-04-01 2018-10-02 Curis, Inc. A thienopyrimidine phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
CN114796501A (zh) 2015-06-25 2022-07-29 免疫医疗公司 抗体与治疗剂的组合治疗癌症的方法
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Also Published As

Publication number Publication date
KR20180108848A (ko) 2018-10-04
US10111864B2 (en) 2018-10-30
US20190091211A1 (en) 2019-03-28
DK2694075T3 (en) 2016-08-01
EP2694075B1 (en) 2016-04-27
TW201247678A (en) 2012-12-01
HRP20160545T1 (hr) 2016-06-17
US20160185796A1 (en) 2016-06-30
SG10201602569RA (en) 2016-05-30
BR112013025340A2 (pt) 2016-12-13
SI2694075T1 (sl) 2016-07-29
US11654136B2 (en) 2023-05-23
EP2694075A1 (en) 2014-02-12
NZ615586A (en) 2015-02-27
CL2013002823A1 (es) 2014-04-11
IL228588A0 (en) 2013-12-31
EP3111938B1 (en) 2019-05-08
US20170304279A1 (en) 2017-10-26
JP6242331B2 (ja) 2017-12-06
US20200215039A1 (en) 2020-07-09
EA022434B9 (ru) 2016-02-29
US20130090335A1 (en) 2013-04-11
AU2012236367B2 (en) 2014-10-09
US8710219B2 (en) 2014-04-29
PL3111938T3 (pl) 2019-09-30
ES2577982T3 (es) 2016-07-19
US11135205B2 (en) 2021-10-05
IL248597A0 (en) 2016-12-29
TWI571469B (zh) 2017-02-21
JP6275784B2 (ja) 2018-02-07
US9249156B2 (en) 2016-02-02
US20220168284A1 (en) 2022-06-02
CN105461736A (zh) 2016-04-06
HRP20191091T1 (hr) 2019-09-20
SMT201600179B (it) 2016-08-31
RS54903B1 (sr) 2016-10-31
JP2018052987A (ja) 2018-04-05
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
EP3111938A1 (en) 2017-01-04
JP2016188255A (ja) 2016-11-04
JP2014509653A (ja) 2014-04-21
EA201301114A1 (ru) 2014-04-30
CN103582483A (zh) 2014-02-12
US9657032B2 (en) 2017-05-23
CN103582483B (zh) 2016-02-17
ME02451B (me) 2016-09-20
EA022434B1 (ru) 2015-12-30
PE20141382A1 (es) 2014-11-04
BR112013025340B1 (pt) 2021-12-21
ZA201406167B (en) 2015-03-25
IL228588A (en) 2016-11-30
RS59219B1 (sr) 2019-10-31
CN105461736B (zh) 2018-06-12
PT3111938T (pt) 2019-07-10
SG193563A1 (en) 2013-11-29
ES2733128T3 (es) 2019-11-27
ME03523B (me) 2020-04-20
HK1194969A1 (zh) 2014-10-31
MX2013011132A (es) 2014-03-12
US10543197B2 (en) 2020-01-28
SI3111938T1 (sl) 2019-08-30
EP2694075A4 (en) 2014-10-01
KR20140023333A (ko) 2014-02-26
NZ705039A (en) 2016-03-31
WO2012135571A1 (en) 2012-10-04
DK3111938T3 (da) 2019-07-01
US20140243330A1 (en) 2014-08-28
CA2830822C (en) 2018-10-02
CA2830822A1 (en) 2012-10-04
AU2012236367A1 (en) 2013-04-18
SMT201900435T1 (it) 2019-09-09
MX340577B (es) 2016-07-13
CY1117785T1 (el) 2017-05-17
PL2694075T3 (pl) 2016-09-30
PT2694075T (pt) 2016-07-11
KR101902325B1 (ko) 2018-09-28
ZA201307082B (en) 2015-04-29
IL248597B (en) 2018-04-30
CY1121825T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
IL237727A0 (en) Inhibitors of phosphoinositide 3-kinase with a zinc-binding group
IL248597A0 (en) A phosphoinositide-3-kinase inhibitor with a zinc binding site
GB2481513B (en) A magazine add-on
ZA201306639B (en) Attachment mechanism for a contaienr
GB201020236D0 (en) A composition for detecting biofilms on viable tissues
EP2611352A4 (en) DISHWASHER
PL2575543T3 (pl) Zestaw do konstruowania stelaża
GB201007327D0 (en) A fireseal
ZA201306307B (en) A fungicidal composition
GB201003609D0 (en) A phantom
GB201002966D0 (en) A bedchair
HUE056022T2 (hu) Eszköz egy fogaskerék rögzítésére
PL2385030T3 (pl) Kompozycja klejowa wolna od emisji
GB2484514B (en) A mechanism
GB201200412D0 (en) A rake
PL2611293T3 (pl) Nowa biocydowa kompozycja
AU332323S (en) A bumper guard
AU332267S (en) A bumper guard
GB201010041D0 (en) Drawer assembly for a vehicle
PH32010000120S1 (en) A rack
GB201116046D0 (en) A cover
GB201116008D0 (en) A kennel
PH32010000289S1 (en) A ballpen
GB201004308D0 (en) New inhibitor compounds